Although response rate was low , disease control rate was higher with combination therapy than with topotecan alone in patients who had platinum-sensitive disease ( 37 % v 18 % ; P = .05 ) and in those who had platinum-refractory disease ( 25 % v 15 % ; P = .14 ) .